Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition Article

Monday, Gourish, Lee, Julieann C, Ravindranathan, Ajay et al. (2020). Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition . 139(6), 1071-1088. 10.1007/s00401-020-02155-5

Open Access

cited authors

  • Monday, Gourish; Lee, Julieann C; Ravindranathan, Ajay; Villanueva-Meyer, Javier E; Tran, Quynh T; Allen, Sariah J; Barreto, Jairo; Gupta, Rohit; Doo, Pamela; Van Ziftle, Jessica; Onodera, Courtney; Devine, Patrick; Grenert, James P; Samuel, David; Li, Rong; Metrock, Laura K; Jin, Lee-way; Antony, Reuben; Alashari, Mouied; Cheshier, Samuel; Whipple, Nicholas S; Bruggers, Carol; Raffel, Corey; Gupta, Nalin; Kline, Cassie N; Reddy, Alyssa; Banerjee, Anu; Hall, Matthew D; Mehta, Minesh P; Khatib, Ziad; Maher, Ossama M; Brathwaite, Carole; Pekmezci, Melike; Phillips, Joanna J; Bollen, Andrew W; Tihan, Tarik; Lucas, John T; Broniscer, Alberto; Berger, Mitchel S; Perry, Arie; Orr, Brent A; Solomon, David A

sustainable development goals

authors

publication date

  • June 1, 2020

keywords

  • Afatinib
  • BILATERAL THALAMIC GLIOMA
  • Bithalamic glioma
  • Clinical Neurology
  • DIAGNOSED GLIOBLASTOMA-MULTIFORME
  • Diffuse midline glioma
  • EGFR
  • ERLOTINIB
  • Erlotinib
  • GENOMIC LANDSCAPE
  • HIGH-GRADE
  • Histone H3
  • Life Sciences & Biomedicine
  • MOLECULAR CHARACTERISTICS
  • MUTATIONS
  • Molecular neuropathology
  • Neurosciences
  • Neurosciences & Neurology
  • Osimertinib
  • PHASE-II
  • Pathology
  • Pediatric cancer
  • RADIATION-THERAPY
  • Science & Technology
  • TEMOZOLOMIDE
  • Trametinib
  • Tyrosine kinase inhibitor

Digital Object Identifier (DOI)

publisher

  • SPRINGER

start page

  • 1071

end page

  • 1088

volume

  • 139

issue

  • 6